Over the last few years artificial intelligence (AI) has emerged as a key trend and an important area for investment in drug discovery, whether in preclinical research workflows, clinical trial design or regulation.

“AI is evolving faster than any other lab technology with new models and approaches such as multimodal and agentic AI emerging every few months. This makes access to skills and expertise increasingly critical if companies are to keep pace with change and apply AI successfully to accelerate R&D,” says Dr Becky Upton, President of the Pistoia Alliance.

This eBook, sponsored by BioIVT, explores the latest AI developments impacting drug discovery, the research areas most likely to benefit and the current limitations of the technology.

Download this exclusive eBook to learn more about:

• How AI is powering drug discovery breakthroughs
• Potential problems with overhyping AI in drug discovery
• Advances in neuroscience powered by AI and supercomputing
• How to unlock hit-to-lead efficiency through AI and automation

Get your copy now.